ArticleClinical oral investigations2016
Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Article in Clinical oral investigations, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Early imaging signs of the use of antiresorptive medication and MRONJ: a systematic review.Clinical oral investigations · 2020Pooled it
- Bone scan index rise prior to osteonecrosis of the jaw with bone-modifying agents in prostate cancer.BJUI compass · 2026Article
- Early detection of medication-related osteonecrosis of the jaw (MRONJ) in patients with metastatic breast cancer using FDG-PET/CT scans.EClinicalMedicine · 2026Article
- ΔBSIJ: a quantitative marker for early detection of medication-related osteonecrosis of the jaw in patients with prostate cancer receiving bone-modifying agents.Annals of nuclear medicine · 2025Article
- Application of navigation system during surgery for medication-related osteonecrosis of the jaw.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2025Article
- Bone scintigraphy and positron emission tomography in the early diagnosis of MRONJ.Open medicine (Warsaw, Poland) · 2025Article
- Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review.Dento maxillo facial radiology · 2021Review
- Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment.Maxillofacial plastic and reconstructive surgery · 2021Article
- Bone metabolism of the jaw in response to bisphosphonate: a quantitative analysis of bone scintigraphy images.Odontology · 2020Article
- Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (1), role of imaging in drug-related osteonecrosis of the jaw: An up-to-date review (secondary publication).The Japanese dental science review · 2019Review
- Review
- Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine.European journal of nuclear medicine and molecular imaging · 2019Review
- Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy.Dento maxillo facial radiology · 2017Article
- Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases.Dentistry journal · 2016Article
- Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ).Dentistry journal · 2016Review
- Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned.Dentistry journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of this study was to evaluate the role of bone scintigraphy (BS) in early prediction of clinically asymptomatic bisphosphonate (BP)-related osteonecrosis of the jaws (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIAL AND
methodsBS of mCRPC patients treated with BP was evaluated for pathologic tracer uptake of the jaws in BS suspicious for BRONJ. Results were compared to development of clinically evident BRONJ. Sensitivity, specificity and predictive values of BS for the detection of BRONJ as well as time from beginning of BP therapy to pathologic tracer uptake in BS and time from pathologic tracer uptake in BS to clinically evident BRONJ were determined.
resultsThirty BP-treated patients were included. Nine patients (30%) had pathologic BS lesions of the jaws. Six patients (20%) developed BRONJ. Sensitivity and specificity of BS for BRONJ prediction were 67 and 79%. Median time from the start of BP treatment to pathologic tracer uptake in BS was 28 months (range 10-33) and from pathologic tracer uptake in BS to clinically evident BRONJ 6.5 months (range 2-19). Pathologic tracer uptake in BS was significantly more often observed in patients who developed BRONJ compared to patients who did not (p = 0.049; OR 7.6).
conclusionsPatients with pathologic tracer uptake in the jaws in BS significantly more often develop BRONJ. An unsuspicious BS is predictive for absence of BRONJ in the future. CLINICAL RELEVANCE: We conclude that when BS has been performed, it should not only be used to assess tumour stage and treatment response but also to check for pathologic tracer uptake in the jaws in BS to detect BRONJ at an early stage in mCRPC patients receiving bisphosphonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.